This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
ECLNegative Net Change UHSPositive Net Change DVANegative Net Change PACBPositive Net Change
medical medical-devices
Intuitive Surgical (ISRG) Rises 10% in a Month: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
JNJPositive Net Change MDTNegative Net Change ISRGNegative Net Change
medical medical-devices
Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?
by Zacks Equity Research
Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.
LHPositive Net Change RMDPositive Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
by Zacks Equity Research
Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes
DVANegative Net Change RMDPositive Net Change DXCMNegative Net Change TNDMNegative Net Change
medical medical-devices
PacBio (PACB) and Form Bio to Boost AAV Industry Development
by Zacks Equity Research
PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.
ECLNegative Net Change UHSPositive Net Change DVANegative Net Change PACBPositive Net Change
medical medical-devices
Implied Volatility Surging for Fresenius Medical (FMS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Fresenius Medical (FMS) stock based on the movements in the options market lately.
FMSPositive Net Change
medical medical-devices
Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.
ECLNegative Net Change DVANegative Net Change MMSINegative Net Change LMATNegative Net Change
medical medical-devices
Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down
by Zacks Equity Research
An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.
DVANegative Net Change RMDPositive Net Change WBAPositive Net Change HIMSPositive Net Change
earnings medical medical-devices
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
BAXNegative Net Change DVANegative Net Change HAENegative Net Change EHCPositive Net Change
medical medical-devices
Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care
by Zacks Equity Research
Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.
ECLNegative Net Change UHSPositive Net Change DVANegative Net Change MASIPositive Net Change
medical medical-devices
Easterly Government Properties (DEA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
DEAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Medical Instruments Picks to Navigate Industry Challenges
by Urmimala Biswas
Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.
HOLXNegative Net Change MASIPositive Net Change VCYTPositive Net Change
medical medical-devices
Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?
by Zacks Equity Research
Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.
RMDPositive Net Change TFXNegative Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices
QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test
by Zacks Equity Research
QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.
RMDPositive Net Change QGENPositive Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
DVANegative Net Change RMDPositive Net Change HOLXNegative Net Change MMSINegative Net Change
medical medical-devices
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
by Zacks Equity Research
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.
CAHPositive Net Change MCKPositive Net Change CORPositive Net Change WBAPositive Net Change
medical medical-devices
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
by Zacks Equity Research
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
ECLNegative Net Change BDXNegative Net Change UHSPositive Net Change DVANegative Net Change
medical medical-devices
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
ECLNegative Net Change DVANegative Net Change LMATNegative Net Change GKOSNegative Net Change
medical medical-devices
Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification
by Zacks Equity Research
Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.
TMOPositive Net Change RMDPositive Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.
SYKNegative Net Change DVANegative Net Change RMDPositive Net Change HOLXNegative Net Change
medical medical-devices
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CNMDNegative Net Change DVANegative Net Change RMDPositive Net Change HOLXNegative Net Change
medical medical-devices
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
ECLNegative Net Change ISRGNegative Net Change DVANegative Net Change LMATNegative Net Change
medical medical-devices
Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices
by Zacks Equity Research
Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.
ECLNegative Net Change UHSPositive Net Change DVANegative Net Change EKSOPositive Net Change
medical medical-devices
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
UHSPositive Net Change DVANegative Net Change HQYPositive Net Change ELVPositive Net Change
medical medical-devices
Boston Scientific (BSX) DBS Programming Software Gets CE Mark
by Zacks Equity Research
Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.
BSXNegative Net Change RMDPositive Net Change MEDPNegative Net Change HIMSPositive Net Change
medical medical-devices